The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

The case emerged following an investigative report by BBC, which uncovered the sale of Aveo-branded combination medicines in ...

FDA officials have identified nine more companies allowed to manufacture and export a banned, lethal drug combination linked ...

Advancements have been made in the pain management field that have successfully found FDA approved alternatives to ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

India’s weak drug regulation is spreading a problem from Africa to America. Reputational damage can be big India’s drug regulators have been caught napping once again. Various pills made by ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...